MREO NASDAQ
Mereo BioPharma Group plc
1W: +2.6%
1M: +42.1%
3M: +20.0%
YTD: -25.6%
1Y: -81.5%
3Y: -71.9%
5Y: -84.2%
$0.38
+0.01 (+3.52%)
Weekly Expected Move ±14.3%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2024-04-15
Earliest Filing
2024-11-12
Latest Filing
partner: 5
Counterparties (Filed by MREO)
5 relationshipsCompanies named in MREO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AstraZeneca AB | AZN | partner | Partner in an amended exclusive license and option agreement for intellectual property rights and assets. | 2024-11-12 | View |
| Ultragenyx Pharmaceutical Inc. | RARE | partner | Partner leading the Phase 3 program for setrusumab and funding the global development program. | 2024-11-12 | View |
| Feng Biosciences Inc. | — | partner | Partner in a global licensing agreement for navicixizumab including milestone payments and royalties. | 2024-11-12 | View |
| ReproNovo SA | — | partner | Partner in an exclusive global license agreement for the development and commercialization of leflutrozole. | 2024-11-12 | View |
| Rubric Capital Management L.P. | — | partner | Extension of cooperation agreement regarding board resignation waiver and termination date. | 2024-04-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-19 | Delisting Notice | View | |
| 2026-08-11 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-05-14 | Shareholder Vote; Exhibits | View | |
| 2026-05-12 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-27 | Officer/Director Change | View | |
| 2026-02-17 | Notice of Delisting or Transfer | View | |
| 2026-01-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-10 | Other Events | View | |
| 2025-05-14 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-12 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2024-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-14 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR